Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.
Q4 2024 Earnings Call Transcript March 12, 2025 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.18, ...
Gross profit for 2024 dropped to $0.5 million ... previously expensed to research and development expenses prior to FDA approval of the 365-day product. Fourth quarter 2024 selling, general ...
The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results